

# The Effect of COVID-19 on Total Joint Arthroplasty

Hailey Worstman<sup>1</sup>, James E. Feng MD, MS<sup>2</sup>, Alex Miller MD<sup>2</sup>, Drew Moore MD<sup>2</sup>

<sup>1</sup>Oakland University William Beaumont School of Medicine, Rochester, MI, USA

<sup>2</sup>Corewell Health William Beaumont University, Royal Oak, Department of Orthopaedic Surgery, Royal Oak, MI, USA

## Introduction

- Arthritis is debilitating disease that is common throughout the U.S. For patients with refractory disease, total hip and knee arthroplasty, collectively known as total joint arthroplasty, are used for definitive management.<sup>1</sup>
- Total joint arthroplasty, TJA, is one of the most common procedures in the U.S. and is typically inpatient in order to start physical therapy and promote joint mobility as soon as possible.
- Elective procedures, including total joint arthroplasties, were halted in March 2020 due to the pandemic.<sup>2,3</sup>
- When TJAs resumed they shifted towards outpatient procedures and at home physical therapy.<sup>4</sup>
- The impact of the COVID-19 pandemic on surgical outcomes is unknown for total joint arthroplasties.

## Aims and Objectives

1

Determine the effect, if any, that COVID-19 had on surgical outcomes for total hip or knee arthroplasties

2

Examine and compare surgical outcomes for patients who had TJA before COVID-19 and during

- Achieving our aims will allow us to understand more comprehensively how COVID-19 affected surgical outcomes, if at all.
- This information could drive changes in pre- and post-operative procedures, such as length of stay after surgery or in-person versus at home physical therapy, among other things.

## Methods

- This was a retrospective study comprised of patients undergoing a total hip or knee arthroplasty at Beaumont Health Royal Oak and Beaumont Health Troy
- Patients had to be greater than 18 years old and had a total hip or knee arthroplasty 4 years prior to the start of COVID-19 (4/01/2016- 3/31/2020) or within the 2 years of COVID-19 (4/01/2020-12/31/2022)
- Data was obtained from the MARQI registry which is a prospective multi-center registry of abstracted data from TJA surgery patient medical records

**Table 1: Surgical Outcomes for Total Knee Arthroplasty**

|                          | Pre-COVID     | COVID        | p-value |
|--------------------------|---------------|--------------|---------|
| <b>ED Visit, n(%)</b>    |               |              | 0.0854  |
| No                       | 9449 (89.9%)  | 3846 (88.9%) |         |
| Yes                      | 1067 (10.1%)  | 480 (11.1%)  |         |
| <b>Mortality, n(%)</b>   |               |              | 0.0561  |
| No                       | 10502 (99.9%) | 4314 (99.7%) |         |
| Yes                      | 14 (0.1%)     | 12 (0.3%)    |         |
| <b>Readmission, n(%)</b> |               |              | 0.0119  |
| No                       | 9603 (91.3%)  | 3894 (90.0%) |         |
| Yes                      | 913 (8.7%)    | 432 (10.0%)  |         |

## Results

**Table 2: Surgical Outcomes for Total Hip Arthroplasty**

|                          | Pre-COVID    | COVID        | p-value |
|--------------------------|--------------|--------------|---------|
| <b>ED Visit, n(%)</b>    |              |              | 0.0070  |
| No                       | 7239 (91.2%) | 3306 (92.7%) |         |
| Yes                      | 698 (8.8%)   | 260 (7.3%)   |         |
| <b>Mortality, n(%)</b>   |              |              | 0.0439  |
| No                       | 7925 (99.8%) | 3554 (99.7%) |         |
| Yes                      | 12 (0.2%)    | 12 (0.3%)    |         |
| <b>Readmission, n(%)</b> |              |              | 0.0066  |
| No                       | 7436 (93.7%) | 3292 (92.3%) |         |
| Yes                      | 501 (6.3%)   | 274 (7.7%)   |         |

Table 1 and 2: 90-day surgical outcomes pre-COVID and during COVID. P-values derived using Chi-square test.

**Table 3: Secondary Outcomes for Total Knee Arthroplasty**

| Procedure Status, n(%)       | Pre-COVID    | COVID        | p-value              |
|------------------------------|--------------|--------------|----------------------|
|                              |              |              | <0.0001 <sup>1</sup> |
| Inpatient                    | 9293 (88.4%) | 527 (19.8%)  |                      |
| Outpatient                   | 1223 (11.6%) | 2141 (80.2%) |                      |
| Missing                      | 0            | 1658         |                      |
| <b>Length of Stay (days)</b> |              |              | <0.0001 <sup>2</sup> |
| N                            | 10516        | 4326         |                      |
| Mean (SD)                    | 2.19 (1.78)  | 1.48 (2.05)  |                      |
| Median                       | 2.00         | 1.00         |                      |
| Range                        | 0.00, 47.00  | 0.00, 34.00  |                      |

Table 3 and 4: Procedure status and length of stay pre-COVID and during COVID. <sup>1</sup>P-values derived using Chi-square test. <sup>2</sup>P-values derived using equal variance two sample t-test

**Table 4: Secondary Outcomes for Total Hip Arthroplasty**

| Procedure Status, n(%)       | Pre-COVID    | COVID        | p-value              |
|------------------------------|--------------|--------------|----------------------|
|                              |              |              | <0.0001 <sup>1</sup> |
| Inpatient                    | 7738 (97.5%) | 511 (22.5%)  |                      |
| Outpatient                   | 199 (2.5%)   | 1760 (77.5%) |                      |
| Missing                      | 0            | 1295         |                      |
| <b>Length of Stay (days)</b> |              |              | <0.0001 <sup>2</sup> |
| N                            | 7937         | 3566         |                      |
| Mean (SD)                    | 1.98 (2.05)  | 1.55 (2.10)  |                      |
| Median                       | 2.00         | 1.00         |                      |
| Range                        | 0.00, 100.00 | 0.00, 28.00  |                      |

## Conclusions

- Compared to pre-COVID-19 total hip and knee arthroplasties, those performed during COVID showed no significant difference in 90-day mortality, ED visits, or readmissions.
- Length of stay was significantly different for hip and knee arthroplasties during COVID-19 compared to prior and admission type shifted more towards outpatient during COVID-19
- Limitations:** All data about procedure status is missing from 2022 total knee and hip arthroplasties
- The results support our hypothesis that surgical outcomes after total joint arthroplasty were minimally impacted by the pandemic due to increased patient screening and various precautions in place
- Shorter lengths of stay and outpatient procedures were associated with favorable surgical outcomes during COVID-19 and continuing these practices may be financially advantageous

## References

- Mandl LA. Determining who should be referred for total hip and knee replacements. *Nat Rev Rheumatol* 2013 96. 2013;9(6):351-357. doi:10.1038/nrrheum.2013.2
- Dittman LE, Johnson JD, Trousdale RT. COVID-19 and elective joint arthroplasty: Patient perspectives and considerations. *Journal of Orthopaedics*. 2021;25:179-185. doi:10.1016/j.jor.2020.05.009
- Bedard NA, Elkins JM, Brown TS. Effect of COVID-19 on Hip and Knee Arthroplasty Surgical Volume in the United States. *Journal of Arthroplasty*. 2020;35(7):S45-S48. doi:10.1016/j.arth.2020.04.060
- Chen AZ, Shen TS, Bovonratwet P, Pain KJ, Murphy AI, Su EP. Total Joint Arthroplasty During the COVID-19 Pandemic: A Scoping Review with Implications for Future Practice. *Arthroplasty Today*. 2021;8:15-23. doi:10.1016/j.artd.2020.12.028

## Acknowledgements

Special acknowledgements to Dr. Michael Flierl, Troy MARCQI site champion, and Dr. Mark Karadsheh, Royal Oak MARQI site champion, for their support and approval of accessing data from the MARCQI registry. Thank you to Michelle Jankowski for statistical consultation. Thank you to Kara Sawarynski, PhD and OUWB School of Medicine for guidance throughout the project.